{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines Cdc20 : Questions médicales les plus fréquentes",
"headline": "Protéines Cdc20 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines Cdc20 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-11",
"dateModified": "2025-04-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines Cdc20"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Complexe promoteur de l'anaphase",
"url": "https://questionsmedicales.fr/mesh/D064173",
"about": {
"@type": "MedicalCondition",
"name": "Complexe promoteur de l'anaphase",
"code": {
"@type": "MedicalCode",
"code": "D064173",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.167.024"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéines Cdc20",
"alternateName": "Cdc20 Proteins",
"code": {
"@type": "MedicalCode",
"code": "D064199",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yangge Du",
"url": "https://questionsmedicales.fr/author/Yangge%20Du",
"affiliation": {
"@type": "Organization",
"name": "Department of Prosthodontics, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, National Clinical Research Center for Oral Diseases, Beijing Key Laboratory of Digital Stomatology, Beijing, China."
}
},
{
"@type": "Person",
"name": "Ping Zhang",
"url": "https://questionsmedicales.fr/author/Ping%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Prosthodontics, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, National Clinical Research Center for Oral Diseases, Beijing Key Laboratory of Digital Stomatology, Beijing, China. Electronic address: zhangping332@hsc.pku.edu.cn."
}
},
{
"@type": "Person",
"name": "Yunsong Liu",
"url": "https://questionsmedicales.fr/author/Yunsong%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Department of Prosthodontics, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, National Clinical Research Center for Oral Diseases, Beijing Key Laboratory of Digital Stomatology, Beijing, China. Electronic address: liuyunsong@hsc.pku.edu.cn."
}
},
{
"@type": "Person",
"name": "Shirly Miniowitz-Shemtov",
"url": "https://questionsmedicales.fr/author/Shirly%20Miniowitz-Shemtov",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel."
}
},
{
"@type": "Person",
"name": "Avram Hershko",
"url": "https://questionsmedicales.fr/author/Avram%20Hershko",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Juxtaposition of Bub1 and Cdc20 on phosphorylated Mad1 during catalytic mitotic checkpoint complex assembly.",
"datePublished": "2022-10-26",
"url": "https://questionsmedicales.fr/article/36289199",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-022-34058-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Design, synthesis and biological evaluation of CDC20 inhibitors for treatment of triple-negative breast cancer.",
"datePublished": "2024-02-08",
"url": "https://questionsmedicales.fr/article/38364716",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejmech.2024.116204"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Prognostic Assessment of CDC20 in Patients with Renal Clear Cell Carcinoma and Its Relationship with Body Immunity.",
"datePublished": "2022-06-08",
"url": "https://questionsmedicales.fr/article/35800227",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/7727539"
}
},
{
"@type": "ScholarlyArticle",
"name": "ASPM, CDC20, DLGAP5, BUB1B, CDCA8, and NCAPG May Serve as Diagnostic and Prognostic Biomarkers in Endometrial Carcinoma.",
"datePublished": "2022-09-17",
"url": "https://questionsmedicales.fr/article/36186000",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/3217248"
}
},
{
"@type": "ScholarlyArticle",
"name": "The intercorrelation among CCT6A, CDC20, CCNB1, and PLK1 expressions and their clinical value in papillary thyroid carcinoma prognostication.",
"datePublished": "2022-07-15",
"url": "https://questionsmedicales.fr/article/35838025",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jcla.24609"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines du cycle cellulaire",
"item": "https://questionsmedicales.fr/mesh/D018797"
},
{
"@type": "ListItem",
"position": 5,
"name": "Complexe promoteur de l'anaphase",
"item": "https://questionsmedicales.fr/mesh/D064173"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines Cdc20",
"item": "https://questionsmedicales.fr/mesh/D064199"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines Cdc20 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines Cdc20",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéines Cdc20",
"description": "Comment diagnostiquer une anomalie de Cdc20 ?\nQuels tests sont utilisés pour évaluer Cdc20 ?\nLes biopsies peuvent-elles détecter Cdc20 ?\nY a-t-il des marqueurs associés à Cdc20 ?\nCdc20 est-il lié à des cancers spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D064199?page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéines Cdc20",
"description": "Quels symptômes sont liés à des anomalies de Cdc20 ?\nLes anomalies de Cdc20 provoquent-elles des douleurs ?\nY a-t-il des symptômes spécifiques au cancer lié à Cdc20 ?\nLes anomalies de Cdc20 affectent-elles l'immunité ?\nCdc20 est-il impliqué dans des syndromes spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D064199?page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéines Cdc20",
"description": "Peut-on prévenir les anomalies de Cdc20 ?\nY a-t-il des facteurs de risque modifiables pour Cdc20 ?\nLes examens réguliers aident-ils à prévenir les problèmes de Cdc20 ?\nL'alimentation influence-t-elle Cdc20 ?\nL'exercice physique a-t-il un impact sur Cdc20 ?",
"url": "https://questionsmedicales.fr/mesh/D064199?page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéines Cdc20",
"description": "Quels traitements ciblent Cdc20 ?\nLa chimiothérapie affecte-t-elle Cdc20 ?\nY a-t-il des thérapies géniques pour Cdc20 ?\nLes traitements ciblés sont-ils efficaces contre Cdc20 ?\nCdc20 peut-il être une cible pour l'immunothérapie ?",
"url": "https://questionsmedicales.fr/mesh/D064199?page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéines Cdc20",
"description": "Quelles complications peuvent survenir avec Cdc20 ?\nCdc20 est-il lié à des métastases ?\nLes anomalies de Cdc20 affectent-elles le pronostic ?\nCdc20 peut-il entraîner des effets secondaires ?\nY a-t-il des risques de rechute liés à Cdc20 ?",
"url": "https://questionsmedicales.fr/mesh/D064199?page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéines Cdc20",
"description": "Quels sont les facteurs de risque pour Cdc20 ?\nL'âge influence-t-il le risque lié à Cdc20 ?\nLe sexe joue-t-il un rôle dans les anomalies de Cdc20 ?\nLes habitudes alimentaires affectent-elles Cdc20 ?\nLe stress est-il un facteur de risque pour Cdc20 ?",
"url": "https://questionsmedicales.fr/mesh/D064199?page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie de Cdc20 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de protéines peuvent identifier des anomalies de Cdc20."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer Cdc20 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'immunoblot et de PCR sont couramment utilisés pour évaluer Cdc20."
}
},
{
"@type": "Question",
"name": "Les biopsies peuvent-elles détecter Cdc20 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les biopsies tumorales peuvent révéler des niveaux anormaux de Cdc20."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs associés à Cdc20 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs tumoraux peuvent être associés à des niveaux élevés de Cdc20."
}
},
{
"@type": "Question",
"name": "Cdc20 est-il lié à des cancers spécifiques ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Cdc20 est souvent surexprimé dans divers types de cancers, comme le cancer du sein."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à des anomalies de Cdc20 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anomalies de Cdc20 peuvent entraîner des symptômes liés à des cancers, comme la fatigue."
}
},
{
"@type": "Question",
"name": "Les anomalies de Cdc20 provoquent-elles des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent provoquer des douleurs associées aux tumeurs, selon leur localisation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au cancer lié à Cdc20 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les anomalies de Cdc20 affectent-elles l'immunité ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent altérer la réponse immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Cdc20 est-il impliqué dans des syndromes spécifiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des syndromes de prédisposition au cancer peuvent être liés à des anomalies de Cdc20."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies de Cdc20 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un mode de vie sain et le dépistage précoce des cancers."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque modifiables pour Cdc20 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter le tabac et l'alcool peut réduire le risque de cancers liés à Cdc20."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à prévenir les problèmes de Cdc20 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement les anomalies."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle Cdc20 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut aider à réduire le risque de cancers."
}
},
{
"@type": "Question",
"name": "L'exercice physique a-t-il un impact sur Cdc20 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut diminuer le risque de cancers associés à Cdc20."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent Cdc20 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de Cdc20 sont en développement pour traiter certains cancers."
}
},
{
"@type": "Question",
"name": "La chimiothérapie affecte-t-elle Cdc20 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains agents chimiothérapeutiques peuvent influencer l'expression de Cdc20."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies géniques pour Cdc20 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches de thérapie génique sont explorées pour corriger les anomalies de Cdc20."
}
},
{
"@type": "Question",
"name": "Les traitements ciblés sont-ils efficaces contre Cdc20 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements ciblés montrent des résultats prometteurs dans les cancers liés à Cdc20."
}
},
{
"@type": "Question",
"name": "Cdc20 peut-il être une cible pour l'immunothérapie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Cdc20 est une cible potentielle pour des approches d'immunothérapie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec Cdc20 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la progression tumorale et la résistance au traitement."
}
},
{
"@type": "Question",
"name": "Cdc20 est-il lié à des métastases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surexpression de Cdc20 est associée à un risque accru de métastases."
}
},
{
"@type": "Question",
"name": "Les anomalies de Cdc20 affectent-elles le pronostic ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les anomalies de Cdc20 peuvent indiquer un pronostic défavorable dans certains cancers."
}
},
{
"@type": "Question",
"name": "Cdc20 peut-il entraîner des effets secondaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements ciblant Cdc20 peuvent provoquer des effets secondaires variés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de rechute liés à Cdc20 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les cancers avec anomalies de Cdc20 présentent un risque de rechute plus élevé."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour Cdc20 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux de cancer et l'exposition à des agents cancérigènes sont des facteurs."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque lié à Cdc20 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de cancers associés à Cdc20 augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans les anomalies de Cdc20 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études montrent que le sexe peut influencer le risque de cancers liés à Cdc20."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires affectent-elles Cdc20 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée peut augmenter le risque de cancers associés à Cdc20."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque pour Cdc20 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut contribuer à un risque accru de cancers liés à Cdc20."
}
}
]
}
]
}
In response to improper kinetochore-microtubule attachments in mitosis, the spindle assembly checkpoint (SAC) assembles the mitotic checkpoint complex (MCC) to inhibit the anaphase-promoting complex/c...
The involvement of CDC20 in promoting tumor growth in different types of human cancers and it disturbs the process of cell division and impedes tumor proliferation. In this work, a novel of Apcin deri...
This article analyzes the relationship between cell division cycle (CDC20) molecules and oncology outcomes in patients with renal clear cell carcinoma (KIRC). CDC20 appears to act as a regulatory prot...
Uterine Corpus Endometrial Carcinoma (UCEC), the most common gynecologic malignancy in developed countries, remains to be a major public health problem. Further studies are surely needed to elucidate ...
CCT6A promotes several carcinomas' growth and invasion in multiple ways, and it relates to CCNB1 and PLK1 through its interaction with CDC20 via protein-protein interaction bioinformatics. This study ...
CCT6A, CDC20, CCNB1, and PLK1 expressions in 186 tumor and 30 non-tumor specimens from PTC patients were determined by immunohistochemical (IHC). Clinical features, disease-free survival (DFS), and ov...
CCT6A, CDC20, CCNB1, and PLK1 expressions were upregulated in tumor tissues compared with non-tumor tissues (all p < 0.001). CCT6A expression positively correlated with CDC20, CCNB1, and PLK1 expressi...
CCT6A, CDC20, CCNB1, and PLK1 are intercorrelated, and they exhibit certain prognostic values in PTC patients....
Cellular senescence is a form of irreversible growth arrest that cancer cells evade. The cell division cycle protein 20 homolog (Cdc20) is a positive regulator of cell division, but how its dysregulat...
The specificity and sensitivity of hepatocellular carcinoma (HCC) diagnostic markers are limited, hindering the early diagnosis and treatment of HCC patients. Therefore, improving prognostic biomarker...
HCC-related datasets were downloaded from the public databases. Differentially expressed genes (DEGs) between HCC and adjacent nontumor liver tissues were then identified. Moreover, the intersection o...
A total of 2,227 upregulated genes and 1,501 downregulated DEGs were obtained in all four datasets, which were mainly found to be involved in the cell cycle and retinol metabolism. Accordingly, 998 OS...
High expression of CDC20 predicted poor survival, as potential target in the treatment for HCC....
Infection virus including HBV and HCV has been well recognized as a major cause inducing hepatocellular carcinoma (HCC). However, molecular investigations into the HTLV-1 (Human T-lymphotropic virus t...
Cell division cycle protein 20 (Cdc20) is a member of the cell cyclin family. In the early stage of mitosis, it activates the anaphase-promoting complex (APC) and forms the E3 ubiquitin ligase complex...
Eukaryotic initiation factor 4A-3 (EIF4A3) is a key component of the exon junction complex (EJC) and is extensively involved in RNA splicing, inducing mRNA decay, and regulating the cell cycle and apo...